Leonhardt’s Launchpads Utah, Inc., an innovation and startup accelerator focused on organ regeneration and recovery technologies, is expanding its research laboratory space and personnel in Salt Lake City, Utah. The company is adding a new dedicated research lab at BioInnovations Gateway and has acquired additional lab research space in Research Park at 417 S. Wakara Way, Suite 3321, Salt Lake City, UT 84108 adjacent to the University of Utah campus. 20 employees and contract researchers will work out of these locations.
This is in addition to office space rented at the C&S Business Incubator and shared lab space previously rented at BioInnovations Gateway. Most of the startups in the innovation accelerator are based on the core IP platform of bioelectric stimulation, micro pumps, endovascular catheters, micro implants and stem cell based organ regeneration compositions.
The company is in the process of launching clinical trials for skin, hair, knees, teeth, diabetic ulcer treatment and heart support in 2018. Eye, brain, liver, kidney, pancreas, breast, aorta, heart, biological pacing and heart valve regeneration technologies are currently in pre-clinical studies in preparation for clinical studies in the future. CancerCell www.cancercellinc.com one of the startups in the accelerator is launching studies in rodents now to test a seven part bioelectric therapy for shrinking cancer tumors without using toxic radiation or chemo therapies. The company has two issued patents in this area already and many more pending. InStim www.instimcell.com has developed a patent pending bioelectric real time treatment for chronic inflammation. PolypStim www.polyp-stim.com is working on technologies intended to shrink polyps, fibroids and cysts and heal associated tissues more rapidly with bioelectric energy. Second Heart Assist, Inc. www.secondheartinc.com is finishing pre-clinical studies with intent to launch clinical trials first in Australia and later in the USA for its circulatory assist support technologies. OrthdodontiCell www.orthodonticell.com is finishing pre-clincial studies with intent to launch clinical trials soon for bioelectric tooth movement acceleration and stabilization, with hope to prove they can safely reduce brace or aligner wearing time by 2/3rds to straighten teeth.
This expansion will increase research and development operations, enabling the company to employ more engineers and biologists, and will provide a foundation to better host visiting research collaborators. Leonhardt inventions – https://patents.justia.com/inventor/howard-j-leonhardt have been used to treat more than 400,000 patients to date and the Leonhardt’s Launchpads Utah team is determined to help build upon Utah’s place on the map already known as leading life science hub.
“Leonhardt’s Launchpads Utah has been operating in the Salt Lake City area since 2015. During that time, we’ve benefited from the amazing talented workforce and first-rate education, research, and healthcare facilities in the area, especially from the University of Utah. After three years we are convinced there may be no better place in the world to build a medical technology enterprise and to do world class research than Utah.” state Howard J. Leonhardt, Executive Chairman & CEO
“We have recruited nearly our entire lab team from graduates of bioengineering, biology or entrepreneurship programs at the University of Utah. They have entered our fast paced research lab running with the skills necessary to help us succeed. We have multiple research initiatives right here in Utah in collaboration with world class researchers at the University of Utah which greatly enhances the communication loop of turning what we learn from early stage tests into continuous product improvements.” stated Dr. Brett Burton, Executive Director of R&D and Startup Launches at Leonhardt’s Launchpads Utah, Inc. a Ph.D. graduate of the U of Utah Bioengineering Program himself.
“Utah is a place were good science, innovative design and quality manufacturing are practiced. We are proud to be growing our presence in this community and look forward to moving forward our multiple research initiatives in collaboration with local scientists, clinicians and partners.” states Dr. Leslie Miller, Chief Medical Officer for Leonhardt’s Launchpads Utah, Inc.
“Leonhardt’s Launchpads Utah, Inc. is the best place to experience an accelerated crash course of the medtech industry for new University of Utah graduates such as myself. From direct hands-on research, to bench-top prototyping, to effective business commercialization and direct communication with the C-suite, Leonhardt’s Launchpads Utah, Inc. is the ideal stimulating experience for career growth with unlimited amounts of exposure that simultaneously fosters learning. With over 20 research projects in various stages of development, the pace is simply astounding. We feel we do more here in a month than many other companies do in a year,” states Kapil K. Sharma, Startup Launch Supervisor & Staff R&D Bioengineer, currently a Professional MBA student, a recent Masters graduate from the Bioengineering BioInnovate program, and the former Co-President of the Bench-to-Bedside Health Entrepreneurship Program all at the University of Utah.
Leonhardt’s Launchpads Utah, Inc. and its Utah based spin out startup Second Heart Assist, Inc. utilize Biomerics a local Utah headquartered contract engineering and OEM manufacturing firm for a number of services for a number of products including heart pacing and infusion leads and circulatory assist pump catheters.
“USTAR, the Governor’s Office of Economic Development, The University of Utah and BioUtah have all been instrumental in fostering our growth in Utah since landing here in 2015. The infrastructure and talent here are outstanding and we believe there may be no better place to grow a medtech company than here.” further stated Howard J. Leonhardt, Executive Chairman & CEO
The grandest long vision project of the team is early stage work to build and test a whole body regeneration chamber – https://vimeo.com/179280204. The accelerator is currently working on a National Science Foundation Small Business Innovation Research (SBIR) grant application with hope to gain seed stage funding for this research.
The innovation and startup accelerator business model is to accelerate each innovation and startup through first-in-man clinical results and then seek out a strategic partner to help develop the product the rest of the way to commercialization.
About Leonhardt’s Launchpads Utah, Inc.:
Founded in 2015 and incorporated in Utah in 2016 an innovation and startup accelerator focused on organ regeneration and recovery technologies primarily based on a core platform of bioelectric stimulators, micro pumps, endovascular catheters, implantable micro devices and stem cell based organ regeneration composition. Web site – https://leonhardtventures.com/leonhardts-launchpads-utah/
About Leonhardt Ventures:
Leonhardt Ventures is the commercialization arm for the inventions of Howard J. Leonhardt and the majority owner of Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. In the 1980’s the team patented and pioneered cardiovascular balloon catheters, in the 1990’s stent grafts and percutaneous heart valves and since 1999 the focus has been on organ regeneration with a combination of bioelectrics and biologics. There are currently 31 startups in the Leonhardt’s Launchpads 2018 portfolio class. Web sites – www.leonhardtventures.com + www.calxstars.com
Selected mentioned startup web sites: www.bioleonhardt.com, www.vascustim.com, www.valvublator.com, www.cerebracell.com, www.cancercellinc.com, www.ear-cell.com, www.polypstim.com www.kidney-cell.com, www.ortho-stim.com, www.skin-stim.com, www.haircellstim.com, www.instimcell.com, www.orthodonticell.com, www.dentacellaccelerator.com, https://leonhardtventures.com/aortacell/,https://leonhardtventures.com/bio-pace/ – others may be found at www.leonhardtventures.com
All product developments mentioned are early stage and unproven yet to be either safe or effective. Any product performance claims implied are not meant to be absolute or deemed proven via statistically significant and powered evaluations. These are early stage optimistic observations only. The company may not have the resources to fully develop these products. Any patents licensed, issued or pending may not be kept active or held. Any strategic partnerships mentioned may not be maintained. Any forward looking statements may be subject to change forward without notice. The communication reflects the optimism of founders and developers only. As an investment these startups must be considered very high risk not suitable for many and restricted to verified accredited and sophisticated experienced investors only at this time. A substantial portion of the engaged team derives sources of income from other sources and may not be fully focused on accomplishing the goals of the organization which may impede or delay progress.